<DOC>
	<DOCNO>NCT01136655</DOCNO>
	<brief_summary>This purpose study investigate bronchodilating effect 3 different dosage formoterol give combination budesonide Symbicort pMDI .</brief_summary>
	<brief_title>A Study Asthmatic Children ( 6 &lt; 12 Yrs ) Comparing Single Doses Formoterol Foradil® Evaluating Efficacy</brief_title>
	<detailed_description>A Phase 2 , randomize , blind , 5-period cross-over , placebo active control , multicenter , dose-finding study compare single dos formoterol 2.25 µg , 4.5 µg , 9 µg deliver via Symbicort pMDI Foradil® 12 µg evaluate relative bronchodilating effect safety child .</detailed_description>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Has document clinical diagnosis asthma least 6 month prior Visit 1 Has FEV1 measure least 6 hour last dose inhale , shortacting β2agonist ( SABA ) least 48 hour last dose inhale longacting β2agonist =60 % =85 % predict normal . Demonstrated reversibility FEV1 =15 % pre short act beta agonist level within 15 30 minute administration standard dose short act beta agonist Has hospitalize &gt; 24 hour least required emergency treatment urgent care visit asthmarelated condition 6 month prior Visit 1 Has require treatment systemic corticosteroid ( eg , oral , parenteral , rectal ) reason within 12 week prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>asthmatic child</keyword>
	<keyword>Symbicort</keyword>
	<keyword>Foradil</keyword>
</DOC>